Goldman Sachs
KYNB

Goldman Sachs’s Kyntra Bio KYNB Stock Holding History

Goldman Sachs’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-220
Closed -$204K – 6151
2020
Q4 		$204K Sell
220
-652
-75% -$685K ﹤0.01% 5082
2020
Q3 		$896K Buy
+872
New +$938K ﹤0.01% 4157
2017
Q3 		– Sell
-1,600
Closed -$1.29M – 6713
2017
Q2 		$1.29M Buy
+1,600
New +$1.11M ﹤0.01% 4224
2016
Q2 		– Sell
-2,456
Closed -$1.31M – 7090
2016
Q1 		$1.31M Buy
2,456
+2,108
+606% +$1.05M ﹤0.01% 3850
2015
Q4 		$265K Buy
348
+188
+118% +$125K ﹤0.01% 5459
2015
Q3 		$88K Buy
+160
New +$96.9K ﹤0.01% 6554

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's KYNB Position: Q2 2025 in Review

Goldman Sachs sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 1,288 shares — an estimated $9.98K sold.

Goldman Sachs first reported a position in KYNB in Q4 2014 and held it in 42 quarters. The position peaked at $46.6M in Q2 2018. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Goldman Sachs reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,288 Kyntra Bio shares in Q2 2025, an estimated $9.98K.
  • Goldman Sachs first reported a position in Kyntra Bio in Q4 2014 and held it in 42 quarters.
  • Goldman Sachs's Kyntra Bio position peaked at $46.6M in Q2 2018.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.